Literature DB >> 2995393

Enzymatic hydration of leukotriene A4. Purification and characterization of a novel epoxide hydrolase from human erythrocytes.

J McGee, F Fitzpatrick.   

Abstract

Human erythrocytes contained a soluble cytosolic epoxide hydrolase for stereospecific enzymatic hydration of leukotriene A4 into leukotriene B4. The enzyme was purified 1100-fold, to apparent electrophoretic homogeneity, by conventional DEAE-Sephacel fractionation followed by high performance anion exchange and chromatofocusing procedures. Its characteristics include a molecular weight of 54,000 +/- 1,000, an isoelectric point 4.9 +/- 0.2, a Km apparent from 7 to 36 microM for enzymatic hydration of leukotriene A4, and a pH optimum ranging from 7 to 8. The enzyme was partially inactivated by its initial exposure to leukotriene A4. There was slow but detectable enzymatic hydration (pmol/min/mg) of certain arachidonic acid epoxides including (+/-)-14,15-oxido-5,8-11-eicosatrienoic acid and (+/-)-11,12-oxido-5,8,14-eicosatrienoic acid, but not others, including 5,6-oxido-8,11,14-eicosatrienoic acid. Human erythrocyte epoxide hydrolase did not hydrate either styrene oxide or trans-stilbene oxide. In terms of its physical properties and substrate preference for leukotriene A4, the erythrocyte enzyme differs from previously described versions of epoxide hydrolase. Human erythrocytes represent a novel source for an extrahepatic, cytosolic epoxide hydrolase with a potential physiological role.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2995393

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  15 in total

Review 1.  Leukotriene A4 hydrolase and the committed step in leukotriene B4 biosynthesis.

Authors:  J Z Haeggström
Journal:  Clin Rev Allergy Immunol       Date:  1999 Spring-Summer       Impact factor: 8.667

2.  Leukotriene A4 hydrolase: protection from mechanism-based inactivation by mutation of tyrosine-378.

Authors:  M J Mueller; M Blomster; U C Oppermann; H Jörnvall; B Samuelsson; J Z Haeggström
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-11       Impact factor: 11.205

3.  Joint tissues amplify inflammation and alter their invasive behavior via leukotriene B4 in experimental inflammatory arthritis.

Authors:  Mei Chen; Bing K Lam; Andrew D Luster; Simona Zarini; Robert C Murphy; Angela M Bair; Roy J Soberman; David M Lee
Journal:  J Immunol       Date:  2010-09-27       Impact factor: 5.422

4.  LTA4 hydrolase in human skin: decreased activity, but normal concentration in lesional psoriatic skin. Evidence for different LTA4 hydrolase activity in human lymphocytes and human skin.

Authors:  L Iversen; B Deleuran; A M Hoberg; K Kragballe
Journal:  Arch Dermatol Res       Date:  1996-05       Impact factor: 3.017

5.  Molecular cloning and amino acid sequence of leukotriene A4 hydrolase.

Authors:  C D Funk; O Rådmark; J Y Fu; T Matsumoto; H Jörnvall; T Shimizu; B Samuelsson
Journal:  Proc Natl Acad Sci U S A       Date:  1987-10       Impact factor: 11.205

6.  Conversion of leukotriene A4 by neutrophils and platelets from patients with atopic dermatitis.

Authors:  R A Hilger; K Neuber; W König
Journal:  Immunology       Date:  1991-12       Impact factor: 7.397

Review 7.  Epoxides and soluble epoxide hydrolase in cardiovascular physiology.

Authors:  John D Imig
Journal:  Physiol Rev       Date:  2012-01       Impact factor: 37.312

8.  Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo.

Authors:  Ding Ai; Yi Fu; Deliang Guo; Hiromasa Tanaka; Nanping Wang; Chaoshu Tang; Bruce D Hammock; John Y-J Shyy; Yi Zhu
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-10       Impact factor: 11.205

Review 9.  Regulation of leukotriene biosynthesis.

Authors:  A W Ford-Hutchinson
Journal:  Cancer Metastasis Rev       Date:  1994-12       Impact factor: 9.264

10.  Hydrolysis of cis- and trans-epoxyeicosatrienoic acids by rat red blood cells.

Authors:  Houli Jiang; Angela G Zhu; Magdalena Mamczur; Christophe Morisseau; Bruce D Hammock; John R Falck; John C McGiff
Journal:  J Pharmacol Exp Ther       Date:  2008-04-29       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.